Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials. SAVA stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback